Neutrophil Extracellular Traps Formation in Breast Cancer Patients Taking Tamoxifen

  • End date
    Oct 31, 2023
  • participants needed
  • sponsor
    M.D. Anderson Cancer Center
Updated on 13 July 2022
breast cancer


This study examines the long-term effects of tamoxifen (TAM) treatment on excessive production of neutrophil extracellular traps (NET) and their impact on breast cancer and side effects. NET are produced by the body to fight infections but have also been linked to side effects caused by the body's immune system. Treatment with tamoxifen increases the production of NETs. This study may help researchers determine if the increased number of NETs in the body has a damaging effect in breast cancer.



I. To examine the effect of long-term tamoxifen (TAM) treatment on excessive NET formation in breast cancer patients.


I. To understand the molecular mechanisms of tamoxifen-induced NET formation in breast cancer patients by examining the effect of long-term TAM treatment on the NET-induced factors.

II. To correlate the extend of NET formation with clinical data on tamoxifen resistance, drug side-effects, cancer metastasis and comorbidities.


I. To explore the association between the extent of NET formation and clinical data for breast cancer patients treated with TAM in combination with other drugs.


Patients undergo collection of blood samples and their medical charts are reviewed.

Condition Breast Carcinoma
Treatment biospecimen collection, Electronic Health Record Review
Clinical Study IdentifierNCT05056857
SponsorM.D. Anderson Cancer Center
Last Modified on13 July 2022


Yes No Not Sure

Inclusion Criteria

Age criteria for pre-menopausal group: Equal to or greater than 18 years of age and less than or equal to 45 years of age. Patients of age 46-50 will be included if they have not had menstrual cessation for 12 consecutive months
Age criteria for menopausal group: At least 51 years of age (median age of menopause). Menopause is defined as cessation of menstrual cycle for 12 consecutive months
Diagnosed with ER+ breast cancer
Being treated with tamoxifen (TAM) for at least 6 months
CONTROL SUBJECTS: Newly diagnosed ER+ breast cancer patients of the same age group as above on TAM for 0-6 months. This criterion is based on our preliminary results showing that patients taking TAM for 6-7 months exhibit near baseline level of NETs

Exclusion Criteria

Patient is terminal (expected survival < 6 months)
Informed consent unobtainable
Pregnant -The immune modulations geared toward maintenance of pregnancy are known to cause wide-spread alterations in innate and adaptive immune cell functions. In this scenario, divorcing the pregnancy-related changes in myeloid cell function from those relevant to sepsis and cancer will be complicated
History of severe congenital neutropenia due to genetic disorders, such as Kostmann Disorder (HAX1 gene mutation), ELA2 gene mutation, Wiskott-Aldrich syndrome (WAS), growth factor independent 1 protein (GFI1) gene mutation, colony stimulating factor 3 receptor (CSF3R) gene mutation, Schwachman-Diamond syndrome, Barth syndrome, warts, hypogammaglobulinemia, infections, and myelokathexis (WHIM) syndrome, and Chadiak-Higashi syndrome (this list notably does not include myelodysplastic syndrome, or acute/chronic myeloid leukemia)
History of autoimmune disorders, which can affect the body's inflammatory response, such as rheumatoid arthritis, lupus, Crohn's disease, multiple sclerosis, and psoriasis
History of chronic viral infections (human immunodeficiency virus [HIV], hepatitis), which can lead to reduced or variable immune cell function
A recent positive coronavirus disease (COVID) test
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note